Share

August 16, 2022; 99 (7 Supplement 1) How to Measure PreventionOpen Access

What Is the Role of Dopamine Transporter Imaging in Parkinson Prevention Clinical Trials?

John Peter Seibyl, Phillip Kuo
First published August 15, 2022, DOI: https://doi.org/10.1212/WNL.0000000000200786
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
378

Share

Article Information

vol. 99 no. 7 Supplement 1 61-67
DOI: 
https://doi.org/10.1212/WNL.0000000000200786
PubMed: 
35970589
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received October 15, 2021
  • Accepted in final form April 11, 2022
  • First Published August 15, 2022.
Copyright & Usage: 
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. John Peter Seibyl, MD and
    2. Phillip Kuo, MD, PhD
  1. John Peter Seibyl, MD and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) GE Healthcare (2) Invicro (3) Life Molecular Imaging (4) Biogen (5) AbbVie (6) MJ Fox Foundation

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. (1) Invicro (2) Likeminds

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Phillip Kuo, MD, PhD
    3. Scientific Advisory Boards:

    1. (1)Amgen (2) General Electric Healthcare

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) General Electric Healthcare (2) Novartis (3) UroToday

    Editorial Boards:

    1. NONE

    Patents:

    1. 1. Patent No. US 10,013,743 B2 by Phillip H. Kuo, Bijan Najafi and Matthew Kupinski. entitled "Systems, Methods and Devices for Performing Motion Artifact Correction" (issued July 3, 2018). Combining wearable sensory technology with reconstruction algorithms for motion correction.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Senior Medical Director for Invicro since July 2020, almost 2 years

    Consultancies:

    1. (1) Amgen (2) Eisai (3) General Electric Healthcare (4) Novartis (5) Invicro (6) Bayer (7)Chimerix (8)Fusion Pharma

    Speakers' Bureaus:

    1. (1) General Electric Healthcare

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. (1) Invicro (75% effort)

    Research Support, Commercial Entities:

    1. (1) General Electric Healthcare (2) Blue Earth Diagnostics

    Research Support, Government Entities:

    1. (1) National Institutes of Health

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. (1) Invicro

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Institute for Neurodegenerative Disorders (J.P.S.), New Haven, CT; Department of Radiology (P.K.), University of Arizona, Tucson; and Invicro, LLC (P.K.), New Haven, CT.
  1. Correspondence
    Dr. Seibyl jseibyl{at}indd.org
View Full Text

Article usage

Article usage: August 2022 to February 2023

AbstractFullPdfSource
Aug 202211263146Highwire
Sep 20222711171Highwire
Oct 2022167847Highwire
Nov 2022155847Highwire
Dec 2022104032Highwire
Jan 2023104818Highwire
Feb 202395317Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me